Provider: View Press Release
Type: Link
Title: Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Description: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease Beyfortus™ is the first monoclonal antibody approved to protect all...
Provider: View Press Release
Type: Link
Title: Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
Description: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment Transaction brings Qunol®, a trusted, profitable double-digit...
Provider: View Press Release
Type: Link
Title: Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
Description: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised Paris, July 28, 2023 Q2 2023 sales growth of 3.3% at CER...
Provider: View Press Release
Type: Link
Title: Press release: Online availability of Sanofi’s half-year financial report for 2023
Description: Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces that its half-year financial report for the...
Provider: View Press Release
Type: Link
Title: Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Description: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease Recommendation for...
Provider: View Press Release
Type: Link
Title: Press Release: Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag
Description: Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative...